Neufahrn / Garching / Munich, Germany, October 24, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, the Technical University of Munich (TUM) and the TUM University Hospital (Klinikum rechts der Isar der Technischen Universität or MRI), today announced a new framework agreement for the research and development of innovative radiopharmaceuticals and radionuclides for the treatment of cancer. This collaboration builds on a long-standing partnership and previously established cooperation agreement between ITM and TUM. The new agreement aims to further accelerate nuclear medicine initiatives by integrating ITM’s expertise in medical radioisotope production and radiopharmaceutical development with TUM’s cutting-edge research capabilities in nuclear physics (FRM II research reactor) and medical applications, alongside MRI’s renowned clinical expertise in diagnostics and patient care. The framework agreement also outlines how ITM and TUM will share and transfer the rights to any results or inventions that come from their future collaboration. Additional details of the framework agreement have not been disclosed.